Craig Husfeld

Craig Husfeld is a synthetic and medicinal chemist with 19 years of pharmaceutical experience. Dr. Husfeld has successfully overseen the synthetic/medicinal chemistry and early-stage CMC work for multiple development stage biotech companies in the analgesic space, including as Director of Medicinal Chemistry at Elysium Therapeutics where he has focused on creating diversion/overdose-resistant opioids.

From 2008 to 2014, Dr. Husfeld was Director of Chemistry at Signature Therapeutics (previously Pharmacofore), where he supported the development of abuse-deterrent opioid prodrugs. Prior to his role at Signature, Dr. Husfeld served as a senior researcher at Theravance Inc.

Dr. Husfeld received a BS in chemistry from University of California, Riverside and a PhD in synthetic organic chemistry from Stanford University.